Results 101 to 110 of about 399,723 (373)

Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile

Yonsei Medical Journal, 2000
Fibrinolytic properties have been detected in animal and human gallbladder (GB) bile. Plasminogen activator inhibitor-1 (PAI-1) has been reported in greater concentration in GB stone bile and may be a nucleating factor in the pathogenesis of GB stone formation. It is unknown whether or not human choledochal bile has similar properties, which could have
S J, Lee, J S, Cho, J P, Chung, K S, Lee, J B, Chung, S I, Lee, Y M, Moon, J K, Kang, S W, Kwon, H S, Chi, J R, Choi, K S, Song   +11 more
openaire   +3 more sources

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction

Diabetes, Metabolic Syndrome and Obesity, 2013
Olga Gruzdeva, Evgenya Uchasova, Yulia Dyleva, Ekaterina Belik, Ekaterina Shurygina, Olga Barbarash Research Institute for Complex Issues of Cardiovascular Diseases under the Siberian Branch of the Russian Academy of Medical Sciences, Kemerovo, Russian ...
Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O   +5 more
doaj  

Spectrophotometric analysis of thrombolytic activity: SATA assay [PDF]

, 2017
Introduction: Measurement of thrombolytic activity i.e. clot lysis is crucial for research and development of novel thrombolytics. It is also a key factor in assessment of the effectiveness of conventionally used thrombolytic agents in the clinic, which ...
Entekhabi, Nazila, Eskandani, Morteza, Farhoudi, Mehdi, Mohammadian, Reza, Rafi, Mohammad, Zamanlu, Masumeh   +5 more
core   +2 more sources

Plasminogen Activator Inhibitor-1 Levels and Polymorphisms

Archives of Pathology & Laboratory Medicine, 2002
Abstract Objective.—To review the published evidence of a relationship between levels of plasminogen activator inhibitor-1 (PAI-1) or the 4G/5G polymorphism of the PAI-1 gene and the occurrence of venous thromboembolic disease. Methods.—Review of the medical literature using computerized databases and a review of secondary
openaire   +2 more sources

Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

American Journal of Hematology, EarlyView.
ABSTRACT Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots.
Jeremy W. Jacobs, Elizabeth A. Abels, Brian D. Adkins, Garrett S. Booth, Victoria Costa, Sheharyar Raza, Michelle Simon, Jennifer S. Woo, Allison P. Wheeler   +8 more
wiley   +1 more source

Identification of a novel regulatory mechanism for the disease associated protein, uPAR [PDF]

, 2014
Expression quantitative trait loci (eQTLs), as determined through a series of statistical association studies collectively known as genome-wide association (GWA) studies, have provided us with a hypothesis free approach for the investigation into ...
Hall, Ian P., Portelli, Michael A., Sayers, Ian   +2 more
core  

Mechanical Stability and Fibrinolytic Resistance of Clots Containing Fibrin, DNA, and Histones [PDF]

, 2013
Neutrophil extracellular traps are networks of DNA and associated proteins produced by nucleosome release from activated neutrophils in response to infection stimuli and have recently been identified as key mediators between innate immunity, inflammation,
Ammollo, Aziz, Borissoff, Brill, Brinkmann, Clark, Esmon, Esmon, Fuchs, Fuchs, Gladysheva, Gleber, Guthold, Komissarov, Komorowicz, Longstaff, Longstaff, Massberg, Nikolova, Rocha, Ruf, Ryan, Rábai, Rácz, Saha, Sands, Scrutton, Semeraro, Silva, Smeeth, Walker, Weisel, Weisel, Wohner, Xu, Yang, Yeromonahos   +36 more
core   +1 more source

Back Again to the Future: A New Era for Cerebroprotection

Annals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction

Journal of Experimental Medicine, 2003
Left ventricular (LV) remodeling after myocardial infarction (MI) results in LV dilation, a major cause of congestive heart failure and sudden cardiac death.
Arman T. Askari, M. Brennan, Xiaorong Zhou, J. Drinko, Annitta Morehead, James D. Thomas, E. Topol, S. Hazen, M. Penn   +8 more
semanticscholar   +1 more source